Allergy Therapeutics Total Liabilities
Allergy Therapeutics total liabilities. Based on the latest financial reports, Allergy Therapeutics (AGY) has total liabilities worth GBX66.75 Million GBX (≈ $8.12K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check AGY asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Allergy Therapeutics (2002–2025)
Total liabilities of Allergy Therapeutics from 2002 to 2025. This chart illustrates how Allergy Therapeutics's total liabilities have evolved over time, based on quarterly financial data.
Allergy Therapeutics Competitors by Total Liabilities
The table below lists competitors of Allergy Therapeutics ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Capital Gearing Trust
LSE:CGT
|
UK | GBX2.47 Million |
|
Rapid Nutrition PLC
PA:ALRPD
|
France | €403.84K |
|
Ampli SA w upadlosci ukladowej
WAR:APL
|
Poland | zł2.19 Million |
|
SEALAND CAP. GA. LS-0001
F:7KM
|
Germany | €4.25 Million |
|
Brave Bison Group PLC
LSE:BBSN
|
UK | GBX33.33 Million |
|
Global Energy Metals Corp
V:GEMC
|
Canada | CA$619.86K |
|
Venture Life Group PLC
LSE:VLG
|
UK | GBX17.76 Million |
Liability Composition Analysis (2002–2025)
This chart breaks down Allergy Therapeutics's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see AGY current and non-current assets.
Liquidity & Leverage Metrics
Allergy Therapeutics Total Liabilities Ratios Explained
Allergy Therapeutics total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 15.71 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.94 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Allergy Therapeutics's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Allergy Therapeutics (2002–2025)
The table below shows the annual total liabilities of Allergy Therapeutics from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | GBX95.74 Million ≈ $11.65K |
+56.64% |
| 2024-06-30 | GBX61.12 Million ≈ $7.44K |
-5.54% |
| 2023-06-30 | GBX64.70 Million ≈ $7.87K |
+83.90% |
| 2022-06-30 | GBX35.18 Million ≈ $4.28K |
-11.05% |
| 2021-06-30 | GBX39.55 Million ≈ $4.81K |
-6.80% |
| 2020-06-30 | GBX42.44 Million ≈ $5.16K |
+37.18% |
| 2019-06-30 | GBX30.94 Million ≈ $3.76K |
+10.57% |
| 2018-06-30 | GBX27.98 Million ≈ $3.40K |
+2.81% |
| 2017-06-30 | GBX27.22 Million ≈ $3.31K |
+3.27% |
| 2016-06-30 | GBX26.36 Million ≈ $3.21K |
+62.38% |
| 2015-06-30 | GBX16.23 Million ≈ $1.97K |
+21.82% |
| 2014-06-30 | GBX13.32 Million ≈ $1.62K |
-6.79% |
| 2013-06-30 | GBX14.29 Million ≈ $1.74K |
+8.59% |
| 2012-06-30 | GBX13.16 Million ≈ $1.60K |
-53.79% |
| 2011-06-30 | GBX28.48 Million ≈ $3.47K |
+12.89% |
| 2010-06-30 | GBX25.23 Million ≈ $3.07K |
-44.25% |
| 2009-06-30 | GBX45.25 Million ≈ $5.51K |
+31.27% |
| 2008-06-30 | GBX34.47 Million ≈ $4.19K |
+123.88% |
| 2007-06-30 | GBX15.40 Million ≈ $1.87K |
+197.37% |
| 2006-06-30 | GBX5.18 Million ≈ $630.01 |
-21.26% |
| 2005-06-30 | GBX6.58 Million ≈ $800.11 |
+58.15% |
| 2004-06-30 | GBX4.16 Million ≈ $505.91 |
-25.78% |
| 2003-06-30 | GBX5.60 Million ≈ $681.60 |
-60.20% |
| 2002-06-30 | GBX14.07 Million ≈ $1.71K |
-- |
About Allergy Therapeutics
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as wel… Read more